Marksans Pharma to acquire 100% of Netherlands-based QliniQ B.V., Strengthening Presence in European Markets

Marksans Pharma Ltd (NSE: MARKSANS | BSE: 524404), one of India's fastestgrowing pharmaceutical companies, today announced that it has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a profitable Netherlands-based pharmaceutical company with established front-end sales, marketing, and distribution capabilities across the Dutch healthcare market.

The acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union.

QliniQ operates a differentiated portfolio of niche pharmaceuticals and medical devices, with established positions across women's health, dermatology, respiratory care, and other specialty categories. The company has developed long-standing relationships across wholesalers, pharmacies, hospitals and insurerled tender channels in the Netherlands, supporting sustainable market access and growth. For the financial year ended 31 December 2025, QliniQ reported revenue of €9.35 million and net profit of €1.01 million. The company has delivered strong profitable growth, with revenue increasing at a CAGR of approximately 41% between FY2023 and FY2025, while maintaining a debt-free balance sheet.

Commenting this acquisition, Albert de Bruin and Raymond Lansink, Board members and Shareholders of QliniQ B.V. said, "We are delighted that QliniQ is becoming part of the Marksans Group. During our discussions with Marksans, we were particularly impressed by the Company's strong track record in product development, its clear long-term vision, and its commitment to quality and innovation. Marksans has built strong product development capabilities, a broad and growing portfolio, and high-quality manufacturing expertise. Combining these strengths with QliniQ's market presence and local expertise creates a compelling opportunity for future growth and value creation. Most importantly, we share a common ambition: to improve access to high-quality medicines and create long-term value for patients, healthcare providers, business partners, and employees. We are excited about the opportunities ahead and look forward to working closely with the Marksans team to build on our shared growth ambitions."

Commenting on the acquisition, Mark Saldanha, Chairman and Managing Director of Marksans Pharma, said, "This acquisition represents an important strategic step in expanding Marksans' presence across regulated European markets. QliniQ has built a profitable niche portfolio supported by established market access capabilities, long-standing customer relationships, and tender participation across the Netherlands healthcare ecosystem. The acquisition provides Marksans with direct access to the Netherlands market and enhances our ability to commercialize existing and future products across regulated European markets. We believe this acquisition will strengthen our long-term growth opportunities and further enhance our global business."

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 246.15 as compared to the previous close of Rs. 248.90. The total number of shares traded during the day was 354014 in over 3869 trades.

The stock hit an intraday high of Rs. 261.00 and intraday low of 240.65. The net turnover during the day was Rs. 88865068.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Pharmaceuticals Acquisition QliniQBV